Company intelligence / Profile preview

ILTOO Pharma

Paris, Île-de-France, Franceiltoopharma.com ↗

Ownership: Private
Development stage: Phase 2

Overview

ILTOO Pharma develops low-dose interleukin‑2 therapies targeting regulatory T cells to restore immune balance in autoimmune, neurological, and inflammatory diseases. Its lead candidate, ILT‑101, has shown promise in systemic lupus erythematosus and ALS through exclusive licensing of MIROCALS consortium data. The company’s approach aims to establish a new standard alongside corticosteroids and anti-TNF antibodies for treating autoimmunity. Clinical results are ongoing with several programs at the Phase II stage or earlier.

Therapeutic areas: NeurologyImmunologyOncologyEndocrinology
Modalities: Low-dose interleukin 2 (IL‑2LD) biotherapies/interleukinsBiosimilars
Industry: Biotech

Drug pipeline

1 asset

Targeted IL-2

Preclinical

Partnerships

MIROCALS ConsortiumGenethon

Beyond the preview

Go deeper on ILTOO Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ILTOO Pharma.

Explore the full profile